Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Turning Point Therapeutics, Inc. | tptx-ex322_7.htm |
| EX-32.1 - EX-32.1 - Turning Point Therapeutics, Inc. | tptx-ex321_8.htm |
| EX-31.2 - EX-31.2 - Turning Point Therapeutics, Inc. | tptx-ex312_11.htm |
| EX-31.1 - EX-31.1 - Turning Point Therapeutics, Inc. | tptx-ex311_9.htm |
| EX-10.20 - EX-10.20 - Turning Point Therapeutics, Inc. | tptx-ex1020_194.htm |
| 10-K - 10-K - Turning Point Therapeutics, Inc. | tptx-10k_20201231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
(1) |
Registration Statement (Form S-3 No. 333-238300) of Turning Point Therapeutics, Inc., and |
|
(2) |
Registration Statement (Form S-8 Nos. 333-231372 and 333-237250) pertaining to the 2013 Equity Incentive Plan (Prior Plan) of Turning Point Therapeutics, Inc., the 2019 Equity Incentive Plan of Turning Point Therapeutics, Inc., and the 2019 Employee Stock Purchase Plan of Turning Point Therapeutics, Inc.;
|
of our reports dated March 1, 2021, with respect to the financial statements of Turning Point Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Turning Point Therapeutics, Inc. included in this Annual Report (Form 10-K) of Turning Point Therapeutics, Inc. for the year ended December 31, 2020.
|
|
|
/s/ Ernst & Young LLP |
|
|
|
|
|
San Diego, California |
|
|
|
March 1, 2021 |
|
|